Apresoline Related Published Studies
Well-designed clinical trials related to Apresoline (Hydralazine)
Hydralazine for essential hypertension. [2011.11.09]
Comparison of the efficacy of nifedipine and hydralazine in hypertensive crisis in pregnancy. [2011.11]
Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial. [2011.01]
A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. [2010.10.08]
Hydralazine for essential hypertension. [2010.08.04]
Effects of dihydralazine on renal water and aquaporin-2 excretion in humans. [2009]
Evidence for the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African-American Heart Failure Trial). [2007.08.15]
Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. [2007.06]
Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. [2007.04.03]
Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. [2006.09]
Antihypertensive therapy in patients with pre-eclampsia: A prospective randomised multicentre study comparing dihydralazine with urapidil. [2006.08]
A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. [2006.05]
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. [2004.11.11]
Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia. [2002.01]
An open trial comparing isradipine with hydralazine and methyl dopa in the treatment of patients with severe pre-eclampsia. [1999.05]
Ketanserin versus dihydralazine in the management of severe early-onset preeclampsia: maternal outcome. [1999.02]
Vasodilator therapy of hypertensive acute left ventricular failure: comparison of captopril-prazosin with hydralazine-isosorbide dinitrate. [1998.11.30]
The haemodynamic effects of ketanserin versus dihydralazine in severe early-onset hypertension in pregnancy. [1998.07]
Treatment of hypertension in patients with pre-eclampsia: a prospective parallel-group study comparing dihydralazine with urapidil. [1998.02]
Dihydralazine or ketanserin for severe hypertension in pregnancy? Preliminary results. [1997.12]
The effect of hydralazine on the development of tolerance to continuous nitroglycerin. [1997.02]
Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. [1995.12]
Effects of lisinopril vs hydralazine on left ventricular hypertrophy and ambulatory blood pressure monitoring in essential hypertension. [1995.08]
Ketanserin and hydralazine in hypertension in pregnancy--a randomised double-blind trial. [1995.06]
Topically applied hydralazine: effects on systemic cardiovascular parameters, blood-aqueous barrier, and aqueous humor dynamics in normotensive humans. [1995.06]
Vasodilator therapy in chronic asymptomatic aortic regurgitation: enalapril versus hydralazine therapy. [1994.10]
Comparison of outcome of labetalol or hydralazine therapy during hypertension in pregnancy in very low birth weight infants. [1993.11]
Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group. [1993.06]
Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group. [1993.06]
Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group. [1993.06]
Malignant ventricular arrhythmias in eclampsia: a comparison of labetalol with dihydralazine. [1993.04]
[Management of severe pre-eclampsia/eclampsia. Comparison between nifedipine and hydralazine as antihypertensive agents] [1993.03]
Comparison of captopril, hydralazine and nifedipine as third drug in hypertensive patients. [1993.02]
A randomized comparison between the hemodynamic effects of hydralazine and nitroglycerin alone and in combination at rest and during isometric exercise in patients with chronic mitral regurgitation. [1993.01]
A comparative study of the use of epoprostenol and dihydralazine in severe hypertension in pregnancy. [1992.09]
Comparative bioavailability of a sustained-release ion-exchange hydralazine product with a potassium (cation) challenge. [1992.06]
Comparative electrophysiological effects of captopril or hydralazine combined with nitrate in patients with left ventricular dysfunction and inducible ventricular tachycardia. [1992.05]
Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. [1992.03.15]
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. [1991.08.01]
Interactions between hydralazine and oral nutrients in humans. [1991.07]
[Management of severe pre-eclampsia in the puerperium. Comparative study of sublingual nifedipine and hydralazine] [1991.07]
Maternal and fetal haemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol. [1991.05]
Which vasodilator drug in patients with chronic heart failure? A randomised comparison of captopril and hydralazine. [1991.01]
Effect of food on oral availability of apresoline and controlled release hydralazine in hypertensive patients. [1990.10]
Hydralazine dose-response curve analysis. [1990.08]
Effects of nifedipine versus hydralazine on sympathetic activity and cardiac function in patients with hypertension persisting on diuretic plus beta-blocker therapy. [1990.04]
Comparative haemodynamic effects of intravenous nisoldipine and hydralazine in congestive heart failure. [1990.03]
Hydralazine does not stimulate prostacyclin biosynthesis in hypertensive patients. [1990.03]
Utilization of hydralazine or alpha-methyldopa for the management of early puerperal hypertension. [1989.10]
Comparative hemodynamic effects of labetalol and hydralazine in the treatment of postoperative hypertension. [1989]
Antihypertensive effect of felodipine or hydralazine when added to beta-blocker therapy. [1988.07]
Long term haemodynamic effects of pinacidil and hydralazine in arterial hypertension. [1988]
Comparison of nifedipine, prazosin and hydralazine added to treatment of hypertensive patients uncontrolled by thiazide diuretic plus beta-blocker. [1987.02]
Comparative efficacy and safety of immediate-release and controlled-release hydralazine in black hypertensive patients. [1987]
Well-designed clinical trials possibly related to Apresoline (Hydralazine)
Left ventricular responses to acute changes in late systolic pressure
augmentation in older adults. [2013]
Pharmacotherapy review of chronic pediatric hypertension. [2011.10]
Atrial fibrillation and mortality in African American patients with heart failure: results from the African American Heart Failure Trial (A-HeFT). [2011.07]
Treatment of heart failure in African Americans--a call to action. [2011.02]
Treatment of heart failure in African Americans--a call to action. [2011]
Heart failure in the ethnic minorities. [2010.03]
Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trial. [2009.12]
Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial. [2009.04]
Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. [2007.11]
Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy. [2005.09]
Endothelial dysfunction and nitric oxide enhancing therapy: a new approach to the treatment of heart failure. [2004.09]
The African-American Heart Failure Trial: background, rationale and significance. [2002.09]
Endogenous endothelin-1 limits exercise-induced vasodilation in hypertensive humans. [2002.08]
African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. [2002.06]
L-arginine augments cardiac vagal control in healthy human subjects. [2002.01]
[Effect of Urapidil in antihypertensive therapy of preeclampsia on newborns] [2001.09]
Left ventricle and arteries: structure, function, hormones, and disease. [2001.02]
The generalizability of trial data; a comparison of beta-blocker trial participants with a prospective cohort of women taking beta-blockers in pregnancy. [2001.02]
The effect of patient positioning on intraabdominal pressure and blood loss in spinal surgery. [2000.09]
Nitric oxide and cardiac autonomic control in humans. [2000.08]
Endothelium-derived nitric oxide contributes to the regulation of venous tone in humans. [2000.01.18]
Donor treatment with phentolamine mesylate improves machine preservation dynamics and early renal allograft function. [2000.01.15]
Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. [1999.09]
Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. [1997.04.01]
Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT) [1996.03.01]
Sublingual nifedipine compared with intravenous hydrallazine in the acute treatment of severe hypertension in pregnancy: potential for use in rural practice. [1996.02]
Oral nifedipine therapy in the management of severe preeclampsia. [1995.06]
Plasma norepinephrine and mortality. [1995.03]
Beta-adrenergic blocking agents in the treatment of pregnancy-induced hypertension. [1995.02]
Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases. [1995]
Differential effects of ACE inhibitors and vasodilators on renal function curve in patients with primary hypertension. [1993.12]
Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. [1993.06]
Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs cooperative studies V-HeFT I and II. V-HeFT VA Cooperative Studies Group. [1993.06]
Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. [1993.06]
Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group. [1993.06]
Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. [1993.06]
Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group. [1993.06]
Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group. [1993.06]
Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. [1993.06]
Influence of age on mechanisms and prognosis of heart failure. The V-HeFT VA Cooperative Studies Group. [1993.06]
The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. [1993.06]
Effect of vasodilator therapy on mortality in chronic congestive heart failure. [1993.05]
The effects of tertatolol on lipid profile. [1993]
Antihypertensive drug effects on placental flow velocity waveforms in pregnant women with severe hypertension. [1992.11]
Non-invasive determination of arterial diameter and distensibility by echo-tracking techniques in hypertension. [1992.07]
Effects of long-term vasodilator therapy on electrocardiographic abnormalities in chronic aortic regurgitation. [1991.10.01]
Early blood pressure control improves pregnancy outcome in primigravid women with mild hypertension. [1991.03.18]
|
